Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 579

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Study of Pembrolizumab and Cyclophosphamide for Patients with Inflammatory Breast Cancer on the Chest Wall

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Study of Hydroxychloroquine Effects in Patients with Resectable Head and Neck Cancer or Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxychloroquine Sulfate

Neuralgia+1

Not recruiting

Study on Lacosamide and Duloxetine for Patients with Chemotherapy-Induced Neuropathic Pain

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Duloxetine

Study of Cabozantinib for Patients with Advanced Renal Cell Carcinoma Previously Treated with One Immunotherapy Drug

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib

Prostate cancer

Not recruiting

Study on the Effect of Adding Leuprorelin Acetate to Radiotherapy for Patients with Oligo-recurrent Prostate Cancer with Up to 4 Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Leuprorelin Acetate

Bladder cancer

Not recruiting

Study of Sasanlimab Treatment as a Bladder-Sparing Strategy in Patients with Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sasanlimab

Study Comparing Venetoclax and Obinutuzumab with Drug Combination for Fit Patients with Untreated Chronic Lymphocytic Leukemia Without Specific Genetic Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab

Huntington's disease

Not recruiting

Study on the Safety and Effects of AMT-130 for Adults with Early Huntington's Disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ifezuntirgene Inilparvovec

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab

Hyperoxaluria

Not recruiting

Long-Term Safety and Efficacy Study of Nedosiran Injection for Patients with Primary Hyperoxaluria

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Nedosiran

Prostate cancer

Not recruiting

Study on Darolutamide with Standard Therapy for Patients with High-Risk Localized Prostate Cancer

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide

Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.